SCOTTISH HEALTH TECHNOLOGIES GROUP North of Scotland Planning Group Karen Macpherson NHS Quality Improvement Scotla

1. SCOTTISH HEALTH TECHNOLOGIES GROUP North of Scotland Planning Group Karen Macpherson NHS Quality Improvement Scotland

2. NHS QUALITY IMPROVEMENT SCOTLAND (NHS QIS) 

3. NHS QUALITY IMPROVEMENT SCOTLAND (NHS QIS) Four key functions: provide advice and guidance on effective clinical practice set clinical and non-clinical standards of care monitor the performance of the NHS against these standards support NHS staff in improving services Central responsibility for patient safety and clinical governance across NHSScotland. Provide support to the Scottish Medicines Consortium and to the Scottish Health Technologies Group.

4. HEALTH TECHNOLOGIES Medicines eg herceptin, antidepressants Medical devices eg hearing aids Procedures eg acupuncture, surgery Setting of care eg midwifery led maternity unit Screening eg breast cancer Processes eg physiotherapy triage of orthopaedic referrals

5. HEALTH TECHNOLOGY ASSESSMENT (HTA)

6. HEALTH TECHNOLOGY ASSESSMENT (HTA)

7. HEALTH TECHNOLOGY ASSESSMENT (HTA) Evidence-based guidance in NHSScotland NICE HTAs (Multiple and Single Technology Assessments) NHS QIS HTAs Scottish Medicines Consortium guidance International HTAs Guidelines � SIGN, NICE, Professional Bodies

8. SCOTTISH HEALTH TECHNOLOGIES GROUP Origin Role Membership Remit Delivery of remit

9. SCOTTISH HEALTH TECHNOLOGIES GROUP Origin Established in 2007 Need for more support and assistance for NHS boards in planning the introduction of new health technologies recommended by NICE and others

10. SCOTTISH HEALTH TECHNOLOGIES GROUP Role Advisory group only SHTG does not make recommendations but aims to provide information to support planning and decision making Uses member networks to communicate information

11. SCOTTISH HEALTH TECHNOLOGIES GROUP Membership SGHD Chief Executives Health Boards, Directors of Medicine, Public Health, Finance & Planning National Procurement NHS QIS Health Economics Lay representation

12. SCOTTISH HEALTH TECHNOLOGIES GROUP Current members Andrew MacLeod Deputy Director, Patients & Quality Division, SGHD (Chair) Harriet Hughes Service Innovation and Transformation, SGHD Sara Davies Medical Advisor, Patients & Quality Division, SGHD James Barbour Chief Executive, NHS Lothian Robert Calderwood Chief Executive, NHS Greater Glasgow & Clyde Tony Wells Chief Executive, NHS Tayside Fiona Ramsay Finance Director, NHS Forth Valley Alison Graham Medical Director, NHS Lanarkshire Heather Knox Regional Planning Director, West of Scotland Carol Davidson Director of Public Health, NHS Ayrshire & Arran Roseanne Urquhart Head of Healthcare Strategy, NHS Highland Derek Yuille Assistant Director of Finance, NHS Ayrshire & Arran Philip Rutledge Consultant in Medicines Management, NHS Lothian Andrew Marsden Medical Advisor, National Procurement Lesley Holdsworth Head of Health Services Research & Effectiveness, NHS QIS Luke Vale Health Economic Research Unit, University of Aberdeen Stella MacPherson Lay Representative Robert Bell Lay Representative

13. SCOTTISH HEALTH TECHNOLOGIES GROUP Remit Horizon scanning Identify existing and new health technologies with potentially significant impact on patient care in NHSScotland, and potential divestment areas Assessment and appraisal Provide assessment and appraisal of health technologies as needed, taking account of both national and international HTAs Facilitating implementation and dissemination Support implementation of evidence-based recommendations on technologies made in NHS QIS HTAs, NICE HTAs and SIGN guidelines

14. SCOTTISH HEALTH TECHNOLOGIES GROUP Delivery of remit Quarterly horizon scanning reports of Health Technology Assessments

15. SCOTTISH HEALTH TECHNOLOGIES GROUP

16. SCOTTISH HEALTH TECHNOLOGIES GROUP Example: Hip protectors for patients in long term care CADTH, Canada �Hip protectors are clinically effective for those at high-risk of hip fracture where a high level of supervision is available. They may be cost effective, dependent on the package of preventative measures in use.�

17. SCOTTISH HEALTH TECHNOLOGIES GROUP Evidence notes Short summary of the published clinical and/or cost-effectiveness evidence for a health technology that is under consideration by decision makers within NHSScotland. eg Clinical and cost-effectiveness of self-monitoring of blood glucose (SMBG) for non-insulin treated type 2 diabetes HTAs eg For which indications is topical negative wound pressure clinically and cost effective?

18. SCOTTISH HEALTH TECHNOLOGIES GROUP Resource & cost impact statements Provide estimates of the resources required and associated financial implications, of implementing key recommendations in HTAs and SIGN guidelines eg SIGN obesity guideline Scoping reports eg. Non-pharmacological management of depression

19. SCOTTISH HEALTH TECHNOLOGIES GROUP New developments Interventional procedures guidance Support to the National Planning Forum Disinvestment Coverage with evidence pilot NICE expansion and diversification

20. SCOTTISH HEALTH TECHNOLOGIES GROUP Challenges Evidence deficiencies Not responding sufficiently on disinvestment Information timeliness Technology not the solution Differing priorities

21. SCOTTISH HEALTH TECHNOLOGIES GROUP Benefits Scotland-wide perspective Inter-agency working Informed evidence-based planning of services Contextualised available evidence to NHS Scotland Opportunity to maximise health gain from the resources available to NHSScotland

22. NORTH OF SCOTLAND PLANNING GROUP What areas should we be concentrating on when horizon scanning? Are there particular topics which planners would like us to look at How can we best support implementation?

23. More Information� http://shtg.nhshealthquality.org SHTG.qis@nhs.net Tracey Savage Project Administrator Tel: 0141 227 3299